Innovative Radiation Therapy Technique Shows Promising Results in Brain Metastasis Management

Researchers from The University of Texas MD Anderson Cancer Center have reported significant advancements in the management of brain metastases through tile-based radiation therapy (TBRT). Presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the findings from the ROADS trial, a multicenter Phase 3 study, reveal promising results for this novel approach.

Led by Dr. Jeffrey Weinberg, professor of Neurosurgery, and Dr. Thomas Beckham, assistant professor of CNS Radiation Oncology, the trial compared TBRT using cesium-131-embedded collagen tiles to the standard postoperative stereotactic radiation therapy (SRT). Their research aimed to improve outcomes for patients undergoing surgical resection for newly diagnosed brain metastases.

The trial demonstrated remarkable improvements for patients receiving TBRT. After one year, recurrence at the surgical site occurred in only 1.3% of patients treated with TBRT, compared to 15.4% in those receiving standard SRT. Additionally, median overall survival for TBRT patients was 42.5 months, significantly surpassing the 17.6 months seen in the SRT group, marking a significant enhancement in patient outcomes.

Dr. Weinberg commented, "Implanting the radioactive tiles at the time of surgery ensures immediate treatment delivery, significantly impacting local tumor control. This method has shown a substantial increase in overall survival compared to standard practices."

The TBRT technique involves implanting FDA-cleared brachytherapy tiles developed by GT Medical Technologies, Inc. during surgery. These tiles deliver low-dose cesium-131 radiation across the surgical cavity, where residual microscopic tumor cells are likely to be present. The radiation is distributed over several weeks, minimizing exposure to healthy tissues and thus limiting potential side effects.

Importantly, the trial found no significant differences in serious treatment-related side effects between TBRT and SRT, confirming the safety and efficacy of the TBRT approach. Patients treated with TBRT experienced faster completion of cranial radiation, which allowed for a prompt return to systemic cancer therapies, potentially enhancing overall cancer management.

Dr. Beckham noted, "The ability to rapidly progress past the challenges of brain metastasis is a significant clinical advancement, getting patients back to broader cancer treatment more swiftly."

The current standard of care for brain metastases involves SRT following surgery to mitigate the risk of recurrence due to remaining microscopic tumor cells. However, logistical and scheduling complications can delay SRT administration, negatively affecting outcomes for some patients. The potential of TBRT to streamline treatment, combined with its impressive efficacy, positions it as an exciting new option in the treatment landscape for brain metastases.

The researchers are hopeful that these findings will support broader adoption of TBRT in clinical settings and pave the way for future studies on its application for other tumor types.